
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 5/1/25**
(See policy history boxes for previous effective dates)

Title: Digital Health Technologies for Attention Deficit/Hyperactivity Disorder

Description/Background

Scope of Review

Software has become an important part of product development and is integrated widely into digital platforms that serve both medical and non-medical purposes. The 3 broad categories of software use in medical devices are:

1. Software used in the manufacture or maintenance of a medical device (eg, software that monitors x-ray tube performance to anticipate the need for replacement),
2. Software that is integral to a medical device or software in a medical device (eg, software used to "drive or control" the motors and the pumping of medication in an infusion pump),
3. Software, which on its own is a medical device referred to as "Software as a Medical Device" (SaMD) (eg, software that can track the size of a mole over time and determine the risk of melanoma).

The International Medical Device Regulators Forum, a consortium of medical device regulators from around the world led by the U.S. Food and Drug Administration (FDA) defines SaMD as "software that is intended to be used for one or more medical purposes that perform those purposes without being part of a hardware medical device".¹ Such software was previously referred to by industry, international regulators, and health care providers as "standalone software," "medical device software," and/or "health software," and can sometimes be confused with other types of software.

The scope of this review includes only those digital technologies that are intended to be used for therapeutic application and meet the following 3 criteria:

1. Must meet the definition of "Software as a medical device" (SaMD) which states that software is intended to be used for a medical purpose, without being part of a hardware medical device or software that stores or transmits medical information.

2. Must have received marketing clearance or approval by the U.S. FDA either through the *de novo* premarket process or 510(k) process or pre-market approval and,
3. Must be prescribed by a healthcare provider.

BCBSA Evaluation Framework for Digital Health Technologies

SaMDs, as defined by the FDA, are subject to the same evaluation standards as other devices. The Blue Cross and Blue Shield Association Technology Evaluation Criterion are as follows:

1. The technology must have final approval from the appropriate governmental regulatory bodies.
2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes.
3. The technology must improve the net health outcome.^a
4. The technology must be as beneficial as any established alternatives.
5. The improvement must be attainable outside the investigational settings.^b

^a The technology must assure protection of sensitive patient health information as per the requirements of The Health Insurance Portability and Accountability Act of 1996 (HIPAA).

^b The technology must demonstrate usability in a real-world setting.

Other regulatory authorities such as the United Kingdom's National Institute for Health and Care Excellence (NICE) have proposed standards to evaluate SaMD.²

Regulatory Status

In April 2020, EndeavorRx (Akili Interactive Labs) received marketing clearance by the U.S. Food and Drug Administration (FDA) through the De Novo premarket review process (DEN200026). EndeavorRx is a prescription device that is indicated to “improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity.” EndeavorRx is intended to be used as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs.

Medical Policy Statement

The use of EndeavorRx is considered **investigational** for all indications including attention-deficit/hyperactivity disorder.

Inclusionary and Exclusionary Guidelines

NA

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

NA

Other codes (investigational, not medically necessary, etc.):

A9291

G0552

G0553

G0554

Note: Individual policy criteria determine the coverage status of the CPT/HCPCS code(s) on this policy. Codes listed in this policy may have different coverage positions (such as established or experimental/investigational) in other medical policies.

Rationale

This evidence review was created in July 2021 with a search of the PubMed database. The most recent literature update. Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

**Digital Technologies for Attention-Deficit/Hyperactivity Disorder
Clinical Context and Therapy Purpose**

Attention-deficit/hyperactivity disorder (ADHD) is a chronic condition characterized by core symptoms of hyperactivity, impulsivity, and inattention, which are considered excessive for the person's age. Both the International Classification of Mental and Behavioral Disorders 10th edition (ICD-10) and the Diagnostic and Statistical Manual of Mental Disorders 5th edition

(DSM-5) require that the symptoms are reported or observed in several settings and that the symptoms of ADHD affect psychological, social, and/or educational/occupational functioning. Prevalence estimates for ADHD vary from 7.2% to 15.5% of children.³

For children younger than 17 years of age, the DSM-5 requires at least 6 symptoms of hyperactivity-impulsivity or at least 6 symptoms of inattention. The combined type requires a minimum of 6 symptoms of hyperactivity-impulsivity plus at least 6 symptoms of inattention. The symptoms must 1) occur often, 2) be present in more than 1 setting, 3) persist for at least 6 months, 4) be present before 12 years of age, 5) impair function in academic, social, or occupational activities, and 6) be excessive for the developmental level of the child.

Treatment may include environmental adjustments, behavioral and psychological interventions, and medications. In some children, these treatments do not sufficiently address symptoms. In others, there may be resistance by the parents to treat children with medications, or there may be other barriers to obtaining established therapies. EndeavorRx is proposed to address these barriers with improved access to care and minimal side effects. The therapy is based on research showing that impairments in attention and cognitive control are associated with lower activation of frontal, frontoparietal, and ventral attention networks. Previously, a game-like intervention was shown to improve cognitive performance and alter the electroencephalogram in the prefrontal cortex in older adults.⁴ The similarity between cognitive control in older adults and attention deficits in ADHD led to the development of EndeavorRx for the treatment of ADHD in children.

The purpose of prescribed therapeutic digital applications is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with attention-deficit/hyperactivity disorder (ADHD).

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is children 8 to 12 years of age with ADHD, with primarily inattentive or combined type ADHD.

Interventions

The digital technology being considered is EndeavorRx. It is a interactive video game that requires the use to navigate a character through a game-like space while collecting objects. It is designed to be played on a mobile device at home for approximately 25 minutes a day, 5 days a week. Typical treatment would be for a period of 1 month, with extension up to 3 months allowed per license.

EndeavorRx uses a proprietary technology platform that adjusts the difficulty level based on the user's prior performance. The adaptive algorithm is intended to encourage the user to surpass their previous performance, so that the user would gradually increase their ability to focus attention. No claims are made for behavioral symptoms such as hyperactivity.

Version 1.5 was reviewed by the U.S. Food and Drug Administration for De Novo marketing clearance. Earlier non-prescription versions were called ProjectEvo and AKL-T01, which was

released under the Enforcement Policy for Digital Health Devices For Treating Psychiatric Disorders During the COVID-19 Public Health Emergency.

EndeavorRx is intended to be used as part of a therapeutic program. EndeavorRx is not intended to be used as a stand-alone treatment

Comparators

Established treatments for ADHD in children include educational, environmental, psychological, and behavioral interventions, and medication. Almost two-thirds of children with ADHD take medication, and about half receive behavioral treatment.³ The following therapies are currently used to treat ADHD, either individually or in combination:

- Educational intervention involves discussion with parents about symptoms and access to services, environmental modifications such as seating arrangements, changes to lighting and noise, reducing distractions, and the benefit of having movement breaks and teaching assistants at school.
- Parent-child behavioral therapy teaches parenting techniques within the principles of behavior therapy. The therapy programs typically last 2 to 3 months and include rewarding positive behavior, identifying unintentional reinforcement of negative behaviors, limiting choices, and using calm discipline.
- Medication with stimulants, such as methylphenidate, are considered first-line therapy for ADHD in school-age children. However, adverse effects of stimulants may include sleep disturbance, decreased appetite, and weight changes. Combination therapy with medication and behavioral interventions can improve both core ADHD symptoms and non-ADHD symptoms such as social skills and parent-child relations.

Outcomes

The general outcomes of interest are change in symptoms of inattention, ability to function at school and home, quality of life, and treatment-related adverse effects.

ADHD-specific rating scales are described in Table 1.

Table 1. ADHD Rating Scales

| Rating Scale | Description | Scoring |
|---|---|---|
| ADHD Rating Scale ⁵ | The ADHD-RS-IV is an 18-item, clinician-administered questionnaire for which a parent respondent rates the frequency of occurrence of ADHD symptoms and behaviors as defined by criteria outlined for ADHD in the DSM-IV. Each item is scored on a 4-point scale ranging from 0 (rarely or never) to 3 (very often) with total scores ranging from 0 to 54. The 18 items are grouped into 2 subscales: hyperactivity/impulsivity and inattentiveness. | Each subscale produces a subscale score ranging from 0 to 27. A higher score indicates more severe ADHD symptoms and behaviors and a negative change in total score indicates improvement |
| The Clinical Global Impression Scale - Improvement ⁶ | The CGI-I is a clinician's comparison of the participant's | The 7-point scale is: 1 = Very much improved, 2=Much improved, |

| | | |
|---|---|--|
| | overall clinical condition at follow-up to the overall clinical condition at baseline. It includes an assessment of the change from the initiation of treatment with a rating from 1 to 7. | 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, and 7=Very much worse. A score of 1, 2, or 3 would indicate overall improvement of ADHD severity. |
| Conners Comprehensive Behavior Rating Scales ⁷ | Parent and teacher forms are available in full (90-item, 59-item) and abbreviated (27-item, 28-item) versions. | Normative values are provided separately by gender and age. |
| The Vanderbilt Assessment Scales for parents and teachers ^{8,9} | The Vanderbilt Assessment Scales are based on DSM-IV scales. The scale for parents has 55 questions that rate symptoms and their impact on family and school. The teacher scale includes 43 questions on symptoms and school performance. | Normative data and percentile ranks are provided for each subscale by grade and gender. |
| Test of Variables of Attention, Attention performance index ¹⁰ | TOVA® is a validated computerized continuous performance test that presents targets and non-targets as squares that either appear at the top or bottom of the screen. The task consists of two halves: the first half has a target-to-non-target ratio assessed sustained attention; the second half assesses inhibitory control. The program assesses attention consistency, attentional lapses, and processing speed. | Clinical meaningfulness for the pivotal trial was defined as: TOVA API improvement greater than 1.4 points, and post-test API score 0 or more (normative range), ADHD-RS improvement of 2 points or more, CGI-I post-score of 1 (very much improved) or 2 or less (very much or much improved), and any improvement in an Impairment Rating Scale. |

ADHD: attention-deficit/hyperactivity disorder; ADHD-RS-IV: ADHD rating scale, version 4; CGI-I: clinical global impression scale-improvement; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders 4th edition; TOVA (API): test of variables of attention (attention performance index).

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

Randomized Controlled Trials

Key RCT characteristics and results are described in Tables 2 and 3. Limitations in study relevance and study design and conduct are described in Tables 4 and 5.

Kollins et al (2020) reported results of the STARS-ADHD (Software Treatment for Actively Reducing Severity of ADHD) randomized double blind trial, which compared treatment with AKL-T01 to a game (EVO Words) that targets cognitive domains other than those targeted by AKL-T01.¹¹ EVO Words requires the child to spell as many words as possible by connecting letters in a grid in a fixed amount of time. Parents and children were informed that the study was evaluating 2 different investigational interventions for ADHD, and only the study coordinator was aware of which video game the children received. Compliance was monitored by study coordinators, who notified parents by email if the game was not played for more than 48 hours. After 4 weeks, patients were reassessed for attentional functioning, ADHD symptoms, and impairment. The primary outcome was the change in the test of variable of attention, attention performance index (TOVA API). Secondary outcomes included a number of clinician and parent reported measures such as the ADHD rating scale, Impairment Rating Scale, and Clinical Global Impressions-Improvement. Out of 348 patients who were randomly assigned, 5 were lost to follow-up, 4 were withdrawn by the parent or investigator, and 10 had invalid test results; there was a final sample of 329 children for the primary outcome measure. The 2 children who received the incorrect allocation were included in the intention-to-treat population. The mean change from baseline on the TOVA API was 0.93 in the AKL-T01 group and 0.03 in the control group ($p < .05$). However, there were no between-group differences for secondary measures, which included the clinician and parent ratings of ADHD symptoms; both groups showed improvement in ADHD ratings from baseline to post-treatment. Treatment-related adverse events AKL-T01 group included frustration (5 [3%] of 180) and headache (3 [2%] of 180) with a mean number of completed sessions of 83%, compared to 96% compliance in the EVO Words group. The study was well-designed and conducted, but there are a number of limitations in study relevance due to the limited age range, limited follow-up, and most importantly the uncertainty of the association of computerized tests with observable behavior. There are also questions regarding what the most effective treatment schedule and characteristics of the patients might be who benefit from this intervention. As was also noted by the trial authors "the results of the current trial are not sufficient to suggest that AKL-T01 should be used as an alternative to established and recommended treatments for ADHD."

Kollins et al (2021) reported results of the STARS-Adjunct study, a multicenter, open-label study of EndeavorRx as an adjunct to pharmacotherapy in children 8 to 14 years of age with ADHD on stimulant medication ($n = 130$) or EndeavorRx alone ($n = 76$).¹² This study design does not permit conclusions about the adjunctive treatment effect of EndeavorRx as both study arms received EndeavorRx. An appropriate study design would be comparing EndeavorRx plus stimulant medication versus stimulant medication alone.

Table 2. Summary of Key RCT Characteristics

| Study; Trial | Countries | Sites | Dates | Participants | Interventions | Comparator |
|---|-----------|-------|--------------|--|---|---|
| Kollins et al (2020); STARS-ADHD ¹¹ (NCT02674633) | US | 20 | 2016 to 2017 | 348 pediatric patients aged 8 to 12 years, with confirmed ADHD, TOVA API scores ≥ 1.8 and below, without or with washout of disorder-related medication. | AKL-T01 (EndeavorRx) for 25 min a day on 5 days per week for 4 weeks (n=180) | EVO Words for 25 min a day on 5 days per week for 4 weeks (n=168) |
| Kollins et al (2021); STARS-Adjunct ¹² , (NCT03649074) | US | 15 | 2018 to 2019 | <p>Inclusion</p> <ul style="list-style-type: none"> Children ages of 8 to 14 years with confirmed ADHD Experiencing suboptimal treatment of ADHD (IRS ≥ 3 overall impairments score) On stimulants cohort participants must have been stable on stimulant medication at an approved dose for ≥ 30 days prior to enrollment and for the no stimulants cohort, participants must be stable off stimulant medication for ≥ 30 days prior to enrollment <p>Primary endpoint</p> <ul style="list-style-type: none"> Change in ADHD-related impairment as measured by the (parent-reported, clinician-rated) from baseline to day 28 | AKL-T01 (EndeavorRx) for 25 min a day on 5 days/week for 4 weeks, followed by a 4-week pause and another 4-week treatment plus stimulant medication (n=130) | AKL-T01 (EndeavorRx) for 25 min a day on 5 days/week for 4 weeks, followed by a 4-week pause and another 4-week treatment only (n=76) |

ADHD: attention-deficit/hyperactivity disorder; IRS: Impairment Rating Scale;

RCT: randomized controlled trial; STARS-ADHD: Software Treatment for Actively Reducing Severity of ADHD; TOVA API: test of variables of attention, attention performance index.US: United States.

Table 3. Summary of Key RCT Results

| Study | TOVA API mean improvement (SD) | TOVA API Improvement >1.4 points n/N (%) | ADHD-Rating Scale Improvement ≥ 2 points n/N (%) | Impairment Rating Scale n/N (%) | Clinical Global Impressions ≤ 2 n/N (%) |
|---|---------------------------------------|--|---|---------------------------------|--|
| Kollins et al (2020); STARS-ADHD ¹¹ | | | | | |
| N | 329 | 329 | 337 | 332 | 339 |
| AKL-T01 | 0.93 (3.15) | 79/169 (47%) | 128/173 (74%) | 82/171 (48%) | 29/175 (17%) |
| EVO Words | 0.03 (3.16) | 51/160 (32%) | 119/164 (73%) | 60/161 (37%) | 26/164 (16%) |
| p-value | <.05 | .006 | .77 | .049 | .86 |
| Kollins et al (2021); STARS-Adjunct ¹³ , | ADHD-IRS Total (Change mean \pm SD) | ADHD-IRS Inattention subscale (Change mean \pm SD) | ADHD-IRS Hyperactivity-Impulsivity subscale | CGI-I (Change mean \pm SD) | IRS overall respondera, n/N (%) |
| N | 128 | 74 | 74 | 74 | - |
| AKL-T01 + stimulants | -6.1 (\pm 7.18) | -3.4 (\pm 4.43) | -2.7 (\pm 3.92) | 3.3 (\pm 0.84) | Day 28: 71/128 (55.5%) Day 84: 77/113 (68.1%) |
| AKL-T01 only | -7.4 (\pm 9.92) | -3.9 (\pm 5.60) | -3.4 (\pm 5.13) | 3.4 (\pm 0.83) | Day 28: 30/74 (40.5%) Day 84: 46/67 (68.7%) |
| p value between groups | Not reported | Not reported | Not reported | Not reported | Not reported |

ADHD: attention deficit/hyperactivity disorder; CGI-I: clinical global impressions scale- improvement; IRS: impairment rating scale; RCT: randomized controlled trial; SD: standard deviation; STARS-ADHD: Software Treatment for Actively Reducing Severity of ADHD; TOVA API: test of variables of attention, attention performance index.^a Proportion of children with ≥ 1 point improvement on IRS Overall Score

The purpose of the study limitations tables (Tables 4 and 5) is to display notable limitations identified in each study. This information is synthesized as a summary of the body of evidence following each table and provides the conclusions on the sufficiency of evidence supporting the position statement. A major limitation identified in the STARS-ADHD study was the study population was not representative of intended use. The trial eligibility criteria only allowed inclusion of children not taking ADHD medication while EndeavorRx is intended to be used as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs. Further, the study duration of 4 weeks was not sufficient to assess long-term impact on ADHD-related impairment and functioning as ADHD is a chronic condition and understanding long-term treatment effects is critically important. Major limitations identified in the STARS-Adjunct study related to the use of an inappropriate comparator. The study compared EndeavorRx plus stimulant medication versus Endeavor Rx alone. This design permits drawing conclusions only about the adjunctive effect of stimulant medication rather than EndeavorRx. Comparing EndeavorRx plus stimulant medication versus stimulant medication alone would be the design to inform the treatment effect of adjunctive EndeavorRx. In addition, the trial did not report statistical comparisons between arms and only reported pre-

and post- differences within each arm. Lastly, the study duration was not sufficient to assess long-term impact on ADHD-related impairment and functioning as ADHD is a chronic condition and understanding long-term treatment effects is critically important. Major limitations in the study design and conduct are summarized in detailed in Table 5.

Table 4. Study Relevance Limitations

| Study | Population ^a | Intervention ^b | Comparator ^c | Outcomes ^d | Duration of Follow-up ^e |
|---|---|---------------------------|--|--|--|
| Kollins et al (2020) ¹¹ | 4. The study population was limited to children 8 to 12 years of age. | | | 7. Other (improvement on computerized tests of attention is weakly associated with classroom attention). | 1. Not sufficient duration for benefit |
| Kollins et al (2021); STARS-Adjunct ¹³ , | | | 5. Other (Study design compared EndeavorRx plus stimulant medication versus Endeavor Rx alone) | 5 and 6. Clinically significant difference not prespecified and not supported. | 1. Not sufficient duration for benefit |

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

^b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

^c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

^d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 5. Study Design and Conduct Limitations

| Study | Allocation ^a | Blinding ^b | Selective Reporting ^c | Data Completeness ^d | Power ^e | Statistical ^f |
|---|--|--|----------------------------------|--|--------------------|--|
| Kollins et al (2020) ¹¹ | | | | 2. Missing data was not included in the intention-to-treat analysis. | | |
| Kollins et al (2021); STARS-Adjunct ¹³ . | 1. Participants not randomly allocated; 4. Inadequate control for selection bias. | 1. Participants or study staff not blinded; 2. Outcome assessors not blinded; | | | | 4. Other (comparative treatment effects not reported; results report only within-group effect) |

| | | | | | | |
|--|--|--|--|--|--|--|
| | | 3. Outcome assessed by treating physician; | | | | |
|--|--|--|--|--|--|--|

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias; 5. Other.

^b Blinding key: 1. Participants or study staff not blinded; 2. Outcome assessors not blinded; 3. Outcome assessed by treating physician; 4. Other.

^c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication; 4. Other.

^d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials); 7. Other.

^e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference; 4. Other.

^f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated; 5. Other.

Section Summary: Digital Therapies for Attention-Deficit/Hyperactivity Disorder

The pivotal single RCT compared outcomes of EndeavorRx to a word game that targeted different cognitive abilities (digital control intervention). Although the experimental treatment group had significantly greater improvement on a computerized test of attention, both the experimental and control groups improved to a similar extent on parent and clinician assessments. The clinical significance of an improvement in a computerized test of attention without a detectable improvement in behavior by parents and clinicians is uncertain. A second open label study compared EndeavorRx plus stimulant medication with EndeavorRx alone. This study design does not permit conclusions about adjunctive treatment effect of EndeavorRx as both study arms received EndeavorRx. An appropriate study design would be comparing EndeavorRx plus stimulant medication versus stimulant medication alone.

Summary of Evidence

For individuals who are children ages 8 to 12 years with ADHD who receive EndeavorRx, the evidence includes a pivotal randomized controlled trial (RCT) and an open label study. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The pivotal RCT compared outcomes of EndeavorRx to a word game that targeted different cognitive abilities (digital control intervention). Although the experimental treatment group had significantly greater improvement on a computerized test of attention, both the experimental and control groups improved to a similar extent on parent and clinician assessments. The clinical significance of an improvement in a computerized test of attention without a detectable improvement in behavior by parents and clinicians is uncertain. A second open label study compared EndeavorRx plus stimulant medication with EndeavorRx alone. This study design does not permit conclusions about the adjunctive treatment effect of EndeavorRx as both study arms received EndeavorRx. An appropriate study design would be comparing EndeavorRx plus stimulant medication versus stimulant medication alone. A number of questions remain concerning the efficacy of this treatment, and additional studies to assess the effect of the digital therapy in adolescents and in children on stimulant medication have recently been completed but not yet published. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Pediatrics

In 2019, the American Academy of Pediatrics (AAP) updated their 2011 clinical practice guideline on the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.³

The guidelines were based on a systematic evidence review by the Agency for Healthcare Research and Quality. The AAP gave strong recommendations based on level A evidence for medications and training and behavioral treatment for ADHD implemented with the family and school.

U.S. Preventive Services Task Force Recommendations

Not applicable

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 6.

Table 6. Summary of Key Trials

| NCT No. | Trial Name | Planned Enrollment | Completion Date |
|------------------|---|--------------------|-----------------|
| <i>Ongoing</i> | | | |
| <i>Published</i> | | | |
| NCT02828644 | Software Treatment for Actively Reducing Severity of ADHD - Follow Up (STARS-ADHD2) | 175 | Feb 2019 |
| NCT03649074 | Software Treatment for Actively Reducing Severity of ADHD as | 203 | August 2023 |

| | | | |
|--------------------|---|-----|------------------------------|
| | Adjunctive Treatment to Stimulant | | |
| Unpublished | | | |
| NCT05183919 | Software Treatment for Actively Reducing Severity of ADHD in Adults (STARS ADHD Adult) | 223 | Jan 2023 (no results posted) |
| NCT04897074 | Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents) | 165 | Sep 2022 (no results posted) |
| NCT03310281 | Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD) | 84 | Nov 2018 (no results posted) |

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

Government Regulations

National:

No NCD

Local:

No LCD

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

Digital Health Technologies: Diagnostic Applications (Behavioral Health Disorders Including Autism Spectrum Disorder)

References

1. International Medical Device Regulators Forum. Software as a Medical Device (SaMD): Key Definitions. 2013. <http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-131209-samd-key-definitions-140901.pdf>. Accessed 1/9/25
2. National Institute for Health and Care Excellence (NICE). Evidence standards framework for digital health technologies. 2021. [Nice.org.uk/corporate/ecd7/chapter/section-a-evidence-for-effectiveness-standards](https://www.nice.org.uk/corporate/ecd7/chapter/section-a-evidence-for-effectiveness-standards). [Overview](#) | [Evidence standards framework for digital health technologies](#) | [Guidance](#) | [NICE](#) Accessed 1/9/25

3. Wolraich ML, Hagan JF, Allan C, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. Oct 2019; 144(4). PMID 31570648
4. Anguera JA, Boccanfuso J, Rintoul JL, et al. Video game training enhances cognitive control in older adults. *Nature*. Sep 05 2013; 501(7465): 97-101. PMID 24005416
5. DuPaul GJ. Parent and teacher ratings of ADHD symptoms: Psychometric properties in a community based sample. *J Clin Child Psychol* 1991; 20:242.
6. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976. Assessed 1/25/23
7. Conners CK. Conners 3rd Edition. Toronto, Multi-Health Systems, Inc., 2008.
8. Wolraich ML, Feurer ID, Hannah JN, et al. Obtaining systematic teacher reports of disruptive behavior disorders utilizing DSM-IV. *J Abnormal Child Psychol*. Apr 1998; 26(2): 141-52. PMID 9634136
9. Wolraich ML, Lambert W, Doffing MA, et al. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. *J Pediatric Psychol*. Dec 2003; 28(8): 559-67. PMID 14602846
10. Forbes GB. Clinical utility of the Test of Variables of Attention (TOVA) in the diagnosis of attention-deficit/hyperactivity disorder. *J Clin Psychol*. Jun 1998; 54(4): 461-76. PMID 9623751
11. Kollins SH, DeLoss DJ, Canadas E, et al. A novel digital intervention for actively reducing severity of pediatric ADHD (STARS-ADHD): a randomized controlled trial. *Lancet Digit Health*. Apr 2020; 2(4): e168-e178. PMID 33334505
12. Kollins SH, Childress A, Heusser AC, et al. Effectiveness of a digital therapeutic as adjunct to treatment with medication in pediatric ADHD. *NPJ Digit Med*. Mar 26 2021; 4(1): 58. PMID 33772095
13. Kollins, S.H., Childress, A., Heusser, A.C. et al. Effectiveness of a digital therapeutic as adjunct to treatment with medication in pediatric ADHD. *npj Digit. Med*. 4, 58 (2021). <https://doi.org/10.1038/s41746-021-00429-0>

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through 1/9/25, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

| Policy Effective Date | BCBSM Signature Date | BCN Signature Date | Comments |
|-----------------------|----------------------|--------------------|---|
| 5/1/23 | 2/21/23 | | Joint policy established. Adopt the BCBSA 3.03.03 Digital Health Therapies for Attention Deficit/Hyperactivity Disorder Policy as written. Vendor Managed (NA) |
| 5/1/24 | 2/20/24 | | Routine Maintenance (jf) Vendor Managed: NA New Policy Title: Digital Health Technologies for Attention Deficit/Hyperactivity Disorder. Removal of "Therapies" and add "Technologies" in the title. Edit to the Medical policy statement. Addition of EndeavorRx Ref added: 1,2,12,13 |
| 5/1/25 | 2/18/25 | | Routine Maintenance (jf) Vendor Managed: NA 2025 Annual HCPCS Added the following codes as E/I G0552,G0553, G0554 effective 1/1/25 (jf) |

Next Review Date: 1st Qtr, 2026

Pre-Consolidation Medical Policy History

| Original Policy Date | Comments |
|----------------------|----------|
| BCN: | Revised: |
| BCBSM: | Revised: |

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: DIGITAL HEALTH TECHNOLOGIES FOR ATTENTION
DEFICIT/HYPERACTIVITY DISORDER

I. Coverage Determination:

| | |
|--|---|
| Commercial HMO (includes Self-Funded groups unless otherwise specified) | Not Covered |
| BCNA (Medicare Advantage) | See Government Regulations Standards |
| BCN65 (Medicare Complementary) | Coinsurance covered if primary Medicare covers the service. |

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.
- Duplicate (back-up) equipment is not a covered benefit.